Title:
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Indication:
Pancreas Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Indication:
Pancreas Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Indication:
Pancreas Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Round Rock
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma
View
Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma
View
Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma
View
Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma
View
Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma
View
Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma
View
Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma
View
Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2
View
Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)
Indication:
Melanoma
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2
View
Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)
Indication:
Melanoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 study in subjects with relapsed or refractory multiple myeloma (Excaliber-RRMM)
View
Description: A Phase 3 Two-Stage Randomized Multicenter Open-label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) versus Daratumumab Bortezomib and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)
Indication:
Myelomas
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 study in subjects with relapsed or refractory multiple myeloma (Excaliber-RRMM)
View
Description: A Phase 3 Two-Stage Randomized Multicenter Open-label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) versus Daratumumab Bortezomib and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)
Indication:
Myelomas
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 study in subjects with relapsed or refractory multiple myeloma (Excaliber-RRMM)
View
Description: A Phase 3 Two-Stage Randomized Multicenter Open-label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) versus Daratumumab Bortezomib and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)
Indication:
Myelomas
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 study in subjects with relapsed or refractory multiple myeloma (Excaliber-RRMM)
View
Description: A Phase 3 Two-Stage Randomized Multicenter Open-label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) versus Daratumumab Bortezomib and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT)
View
Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT)
View
Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT)
View
Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT)
View
Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT)
View
Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer
View
Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer
View
Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)
View
Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)
View
Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)
View
Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Extension Trial Pembro Adv Tumors
View
Description: A Multicenter Open-label Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (MK3475-587)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Extension Trial Pembro Adv Tumors
View
Description: A Multicenter Open-label Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (MK3475-587)
Indication:
Solid Tumors
Location:
Texas Oncology-South Austin
Phase: III